Login
REGENXBIO NASDAQ: RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects
| Name | REGENXBIO |
| Ticker | RGNX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
|
Price
52W Low/High |
40.91
21.50 / 49.95 |
| Momentum | Weak Down |
| Market cap | 1.5 B |
| 1Y Total Return |
2.27%
Below Average |
| 1Y Volatility |
73.01%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects
Details
| Ticker | RGNX |
| Name | REGENXBIO |
| ISIN | US75901B1070 |
| CUSIP | 75901B107 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 2/26/21
| Close Price | 40.91 |
| 52W Low/High | 21.50 / 49.95 |
| Market cap | 1.5 B |
| 1Y Total Return |
2.27%
Below Average |
| 1Y Volatility |
73.01%
More Risk |
| Beta | 1.87 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -63.1% |
| Cash from Op. / Cur. Liabilities | -1.87 |
| Diluted Earnings / Share | -2.48 |
| ROE | - |
| ROIC | -23.1% |
| Price / Revenue | 11.0 |
| Price / Book | 3.8 |
| Price / CF | -13.4 |
| Current Ratio | 6.1 |
| Cur.Liabilities / Tot.Liabilities | 0.5 |
| Financial Leverage | 0.15 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
145
|
64
|
180
|
10
|
7
|
4
|
|
| Gross Profit |
116
|
57
|
173
|
8
|
6
|
4
|
|
| R&D |
153
|
115
|
74
|
59
|
34
|
15
|
|
| EBITDA |
-86
|
-56
|
86
|
-75
|
-48
|
-20
|
|
| Operating Income |
-106
|
-106
|
69
|
-80
|
-50
|
-20
|
|
| Net Income exc. Extra |
-
|
-
|
80
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
39
|
37
|
34
|
31
|
26
|
5
|
|
| EPS exc. Extra |
-2.48
|
-1.81
|
2.27
|
-2.70
|
1.24
|
-6.67
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
541
|
509
|
515
|
209
|
196
|
227
|
|
| Cash, Eq & Invt ShortTerm |
243
|
333
|
373
|
167
|
92
|
213
|
|
| Total Current Assets |
387
|
360
|
386
|
172
|
97
|
215
|
|
| Total Non-Current Assets |
154
|
149
|
129
|
37
|
99
|
12
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
126
|
41
|
21
|
15
|
16
|
6
|
|
| Total Current Liabilities |
64
|
31
|
19
|
13
|
14
|
5
|
|
| Long Term Debt |
62
|
9
|
2
|
1
|
1
|
0
|
|
| Shareholder equity |
416
|
468
|
494
|
195
|
180
|
222
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-119
|
-86
|
95
|
-65
|
-33
|
-18
|
|
| Depreciation |
8
|
7
|
3
|
2
|
0
|
0
|
|
| Cash from Investing |
125
|
12
|
-213
|
14
|
-142
|
-19
|
|
| Capex |
15
|
16
|
10
|
9
|
4
|
0
|
|
| Cash from Financing |
8
|
12
|
201
|
83
|
-2
|
242
|
|
| Stock Issued |
8
|
12
|
201
|
83
|
-3
|
148
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
89
|
-94
|
-80
|
-129
|
-99
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
44.3%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
137.5%
|
-
|
-
|
-
|
|
| Current Ratio |
6.1
|
11.5
|
20.2
|
12.8
|
6.7
|
40.6
|
|
| Financial Leverage D/E |
0.15
|
0.01
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-23.1%
|
-16.5%
|
34.7%
|
-53.0%
|
-57.1%
|
-237.7%
|
|
| Return on Shareholder Equity |
-
|
-
|
23.1%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available